Alexey Larionov
Larionov, Alexey (Alexey A.)
VIAF ID: 355144782714564820475 (Personal)
Permalink: http://viaf.org/viaf/355144782714564820475
Preferred Forms
- 100 0 _ ‡a Alexey Larionov
- 100 1 _ ‡a Larionov, Alexey ‡q (Alexey A.)
-
4xx's: Alternate Name Forms (3)
Works
Title | Sources |
---|---|
Ability of lymphocytes infiltrating breast-cancer tissue to convert androstenedione. | |
Aromatase (CYP19) expression in tumor-infiltrating lymphocytes and blood mononuclears | |
Aromatase in breast cancer tissue ? localization and relationship with reproductive status of patients | |
Aromatase in skeletal muscle. | |
Aromatase inhibitors--gene discovery | |
Bridging the gap between translational research and clinical application | |
C35 overexpression defines subsets of human breast cancer and its immunoreceptor tyrosine-based activation motif represents a novel treatment target. | |
Changes in breast cancer transcriptional profiles after treatment with the aromatase inhibitor, letrozole | |
Direct integration of intensity-level data from Affymetrix and Illumina microarrays improves statistical power for robust reanalysis | |
Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole | |
Germline pathogenic variants in PALB2 and other cancer-predisposing genes in families with hereditary diffuse gastric cancer without CDH1 mutation: a whole-exome sequencing study. | |
High prevalence and breast cancer predisposing role of the BLM c.1642 C>T (Q548X) mutation in Russia | |
High prevalence of GPRC5A germline mutations in BRCA1-mutant breast cancer patients. | |
Integrative analyses identify modulators of response to neoadjuvant aromatase inhibitors in patients with early breast cancer | |
Local uptake and synthesis of oestrone in normal and malignant postmenopausal breast tissues | |
Malta (MYH9 Associated Elastin Aggregation) Syndrome: Germline Variants in MYH9 Cause Rare Sweat Duct Proliferations and Irregular Elastin Aggregations | |
Molecular Changes in Lobular Breast Cancers in Response to Endocrine Therapy | |
Molecular effects of oestrogen deprivation in breast cancer | |
Neoadjuvant therapy of endometrial cancer with the aromatase inhibitor letrozole: endocrine and clinical effects. | |
Personalization of loco-regional care for primary breast cancer patients (part 2). | |
The pro-metastatic protein anterior gradient-2 predicts poor prognosis in tamoxifen-treated breast cancers | |
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features | |
A standard curve based method for relative real time PCR data processing | |
Translation elongation factor eEF1A2 is a potential oncoprotein that is overexpressed in two-thirds of breast tumours | |
Treatment with aromatase inhibitors stimulates the expression of epidermal growth factor receptor-1 and neuregulin 1 in ER positive/HER-2/neu non-amplified primary breast cancers. | |
Understanding the mechanisms of aromatase inhibitor resistance | |
Use of microarray analysis to investigate EMT gene signatures | |
Value of bilateral breast cancer for identification of rare recessive at-risk alleles: evidence for the role of homozygous GEN1 c.2515_2519delAAGTT mutation |